title: Ten years single institutional experience of treatment for advanced hypopharyngeal cancer in Kyoto University.
abstract: CONCLUSIONS
  Treatment of advanced hypopharyngeal cancer has become more conservative and more multidisciplinary, and the prognosis has been improved. Induction chemotherapy has the potential to extend organ preservation therapy even in cases with locally advanced primary lesion. It is also important to develop a strategy to reduce distant metastasis and to keep track of second primary cancers.
  
  
  OBJECTIVE
  To update the therapeutic outcome of advanced hypopharyngeal cancer.
  
  
  METHODS
  A total of 72 cases with stage III/IV hypopharyngeal cancer were treated at Kyoto University Hospital during 2000-2008. Surgery was performed in 56 cases; total pharyngolaryngoesophagectomy (TPLE) in 39 cases and partial pharyngectomy (PPX) preserving the larynx in 17 cases. Radiotherapy (RT) with or without concurrent chemotherapy was applied in 16 cases. Induction chemotherapy (ICT) has been applied for 14 cases since 2006 to achieve organ preservation and reduction of distant metastasis. The follow-up period varied from 12 months to 96 months (mean 32 months). Therapeutic outcomes were chart reviewed.
  
  
  RESULTS
  Five years cumulative overall and disease-specific survival (DSS) rates were 52.1% and 63.8%, respectively. DSS rates in cases treated with surgery and those with RT were 65.1% and 56.1%, respectively. N2c status showed the worst prognosis according to nodal disease classification. Local control rates for cases treated with TPLE, PPX, and RT were 97.3%, 100%, and 80.4%, respectively. The effective rate of ICT was 79%, and laryngeal preservation was achieved in 79% of the cases with ICT. Recurrence occurred in 20 cases. Approximately half of the recurrence was distant disease. In the end, 17 cases died of the primary disease, while 10 cases died of other causes, mainly second primary cancers.
authors.affiliation: Department of Otolaryngology Head and Neck Surgery, Kyoto University, Sakyo-ku, Kyoto, Japan. hirano@ent.kuhp.kyoto-u.ac.jp
authors.forename: Shigeru
authors.initials: S
authors.lastname: Hirano
authors.forename: Ichiro
authors.initials: I
authors.lastname: Tateya
authors.forename: Morimasa
authors.initials: M
authors.lastname: Kitamura
authors.forename: Shinpei
authors.initials: S
authors.lastname: Kada
authors.forename: Seiji
authors.initials: S
authors.lastname: Ishikawa
authors.forename: Tomoko
authors.initials: T
authors.lastname: Kanda
authors.forename: Shinzo
authors.initials: S
authors.lastname: Tanaka
authors.forename: Juichi
authors.initials: J
authors.lastname: Ito
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D003131:Combined Modality Therapy; D005260:Female; D006785:Hospitals, University; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D007564:Japan; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010611:Pharyngectomy; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome